Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Mouridsen

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupA Santoro, T Tursz, H Mouridsen, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1987
VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma groupP Dombernowsky, J Buesa, H M Pinedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1989
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma GroupT A Alvegård, H Sigurdsson, H Mouridsen, et al.
Seminars in Surgical Oncology|January 1, 1988
Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of CancerV H Bramwell, A Santoro, J Rouesse, et al.
Pharmacoeconomics|July 6, 1997
Comments on economic evaluation of chemotherapyS R Clausen, V Jøjnsson, M M Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)L Beex, C Rose, H Mouridsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysisP Dombernowsky, H Mouridsen, J Schütte, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B TrialM Andersson, C Kamby, M B Jensen, et al.
Seminars in Oncology|February 1, 1992
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma GroupG Blackledge, W P Steward, J Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancerJ Pedersen-Bjergaard, T C Sigsgaard, D Nielsen, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1995
Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma GroupA Santoro, T Tursz, H Mouridsen, et al.
European Journal of Cancer & Clinical Oncology|May 1, 1987
VP-16 in advanced soft tissue sarcoma: a phase II study of the EORTC soft tissue and bone sarcoma groupP Dombernowsky, J Buesa, H M Pinedo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 1, 1989
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma GroupT A Alvegård, H Sigurdsson, H Mouridsen, et al.
Seminars in Surgical Oncology|January 1, 1988
Review of the clinical trials activity of the Soft Tissue and Bone Sarcoma Group of the European Organization for Research and Treatment of CancerV H Bramwell, A Santoro, J Rouesse, et al.
Pharmacoeconomics|July 6, 1997
Comments on economic evaluation of chemotherapyS R Clausen, V Jøjnsson, M M Hansen, et al.
European Journal of Cancer (Oxford, England : 1990)|October 19, 2006
Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)L Beex, C Rose, H Mouridsen, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1986
Phase II study of ifosfamide + adriamycin in advanced soft tissue sarcoma in adults. A preliminary analysisP Dombernowsky, H Mouridsen, J Schütte, et al.
European Journal of Cancer (Oxford, England : 1990)|February 16, 2000
Tamoxifen in high-risk premenopausal women with primary breast cancer receiving adjuvant chemotherapy. Report from the Danish Breast Cancer co-operative Group DBCG 82B TrialM Andersson, C Kamby, M B Jensen, et al.
Seminars in Oncology|February 1, 1992
Experience with ifosfamide in the EORTC Soft Tissue and Bone Sarcoma GroupG Blackledge, W P Steward, J Verweij, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1992
Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancerJ Pedersen-Bjergaard, T C Sigsgaard, D Nielsen, et al.
Pageof 6